GlassScriptPhysician profile
Dorela Shtjefni
NPI 1902552367
$8,137.89
in general payments reported to CMS, 2019-2025
31 companies · $2,371 in 2025
The $2,371 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,612 · 2023: $1,711 · 2024: $2,444 · 2025: $2,371.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,426 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,425.71 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,641.65 | 2022-2025 | Airsupra, Fasenra, Tezspire |
| Glaxosmithkline, LLC. | $1,165.35 | 2022-2025 | Nucala, Trelegy Ellipta |
| Takeda Pharmaceuticals U.S.A., INC. | $951.53 | 2022-2025 | Hyqvia, Eohilia, Takhzyro |
| Genzyme Corporation | $938.36 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $678.03 | 2022-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $510.74 | 2022-2025 | |
| Csl Behring | $487.07 | 2022-2025 | Haegarda, Hizentra, Andembry |
| Amgen INC. | $352.24 | 2024-2025 | Tezspire |
| Alk-Abello, INC | $209.88 | 2022-2025 | Ragwitek, Grastek, Odactra |
| Genentech USA, INC. | $198.88 | 2023-2025 | Xolair |
| Teva Pharmaceuticals USA, INC. | $164.23 | 2022 | |
| Ars Pharmaceuticals Operations, INC. | $103.97 | 2025 | Neffy |
| Sanofi-Aventis U.S. LLC | $99.95 | 2024 | |
| Kaleo, INC. | $96.84 | 2022-2024 | Auvi-Q |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.19 | 2022-2023 | Spiriva Respimat |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $71.04 | 2022-2023 | |
| Organon LLC | $49.10 | 2025 | Vtama |
| Abbvie INC. | $42.99 | 2022 | |
| Hikma Pharmaceuticals USA | $29.19 | 2024 | Ryaltris |
| Biocryst US Sales Co., LLC | $27.31 | 2023 | Orladeyo |
| Mylan Specialty L.P. | $27.28 | 2024 | Yupelri |
| Pharming Healthcare, INC. | $26.62 | 2024 | Ruconest |
| Aimmune Therapeutics, INC. | $25.52 | 2022 | |
| Leo Pharma INC. | $24.97 | 2023 | Adbry |
| Covis Pharma Gmbh | $24.40 | 2022-2023 | |
| Hospira, INC. | $22.81 | 2024 | |
| Octapharma USA, INC. | $21.17 | 2023 | Cutaquig |
| Galderma Laboratories, L.P. | $19.57 | 2025 | Nemluvio |
| Merck Sharp & Dohme LLC | $18.45 | 2023 | |
| Paratek Pharmaceuticals, INC. | $18.00 | 2025 | Xhance |
| Dermavant Sciences, INC. | $15.56 | 2024 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dorela Shtjefni listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.